It is controversial whether there is efficacy or safety benefit of epidermal growth factor
receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell …

Objectives The optimal sequence for the administration of epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) for treating non‐small cell lung cancer (NSCLC) is …

Acquired resistance to epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors
(TKI s) is a prevalent clinical problem in the management of advanced non‐small‐cell lung …

Objective Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …

Multiple randomized clinical trials have demonstrated that epidermal growth factor receptor
(EGFR) exon 19 deletion (19Del) and exon 21 L858R mutation (L858R) are highly …

Background Vascular mimicry (VM) was associated with the prognosis of cancers. The aim
of the study was to explore the association between VM and anticancer therapy response in …

Gefitinib, the first-generation epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI), has become the standard of care for the first-line of therapy for advanced non …

Worldwide, lung cancer is the most prevalent form of cancer, and its non–small-cell subtype
constitutes up to 85% of cases. Overall, lung cancer is the most common cause of cancer …

Aim: This study investigated the association between clinical data and T790M mutation in
rebiopsy after EGFR tyrosine kinase inhibitors (EGFR-TKIs) failure, and explored the …

Purpose This single-center, open-label, single-arm, phase II clinical trial aimed to examine
the efficacy and safety of the first-generation EGFR-TKIs combined with chemotherapy …